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Abstract
Background: Although the introduction of novel agents improved the survival outcomes in patients with multiple
myeloma (MM), some patients died within one year (early mortality, EM) following diagnosis. In this study, we
evaluated the EM rate, and investigated the risk factors associated with EM in MM patients.
Methods: Retrospective data from 542 patients who were initially treated with a novel agent-containing
regimen were analyzed.
Results: The median overall survival (OS) for the entire cohort was 56.5 months. The median OS in the 2010–2014
group was longer than in the 2002–2009 group (59.2 months vs. 49.1 months, P = 0.054). The rate of EM was
13.8 %, and the most common causes of EM were infection and comorbidity. In multivariate analysis, the age-adjusted
Charlson comorbidity index (ACCI ≥ 4), low body mass index (BMI < 20 kg/m2), thrombocytopenia, and renal
failure were significantly associated with EM. The presence of none, 1, or ≥ 2 factors was associated with a 4.1 %,
14.3 %, or 27.4 % risk of EM (P < 0.001), respectively. The median OS times were significantly different depending
on the presence of factors associated with EM (P < 0.001).
Conclusions: In conclusion, the ACCI (≥ 4), low BMI, thrombocytopenia and renal failure were strong predictors
for EM in the novel agent era. The results of this study will help to identify patients at high risk for EM, and may
be helpful to more accurately predict prognosis of MM patients in the novel-agent era.
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Background
Multiple myeloma (MM) is a clonal B-cell malignancy
characterized by aberrant expansion of malignant plasma
cells in bone marrow [1]. MM accounts for 1 % of all can-
cers and more the 10 % of all hematologic malignancies in
the United States [2]. In Asian countries, the incidence
of MM is lower than that of Western countries, but is
increasing rapidly [3]. Treatment options for MM have
expanded since the introduction of melphalan in the
1960s. The median survival of MM patients was less
than a year prior to the introduction of this alkylating
agent, and treatment with melphalan improves survival
[4]. In the 1980s, the introduction of high-dose chemo-
therapy followed by autologous stem cell transplant-
ation (HDT/ASCT) improved the response rate and
survival [5–8]. Induction therapy with alkylating agents,
anthracyclines and corticosteroid, and HDT/ASCT
were the main treatment strategy in MM patients.
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These treatment paradigms have markedly changed fol-
lowing the introduction of several new agents such as
proteasome inhibitor bortezomib, the immunomodula-
tory drug thalidomide, and its derivative lenalidomide.
Treatments with more effective and less toxic agents
improved the response rate in relapsed or refractory
disease [9, 10]. Additionally, their use during induction
resulted in considerable improvement of outcomes and
extended the overall survival (OS) times [11, 12]. The
treatment improvements in MM patients also affected
early mortality (EM), defined as death within 1 year of
diagnosis. A recent single center report showed improve-
ment in EM over the last decade in a large –volume, ter-
tiary MM center [13]. However, 10 % of patients still died
within 1 year of diagnosis, and the cause and risk factors
for EM have not been thoroughly explored in the novel-
agent era.
In this study, we evaluated the EM rate and investi-
gated risk factors associated with EM in MM patients
initially treated with novel-agent containing regimen.
Methods
Patients
This retrospective study analyzed the records of 542 pa-
tients with newly diagnosed MM between September
2002 and February 2014 from three institutions in the
Republic of Korea. Patients who were initially treated
with novel agents such as immunomodulatory drug or
proteasome inhibitors were included. Patients diagnosed
with monoclonal gammopathy of undetermined signifi-
cance, asymptomatic MM, and plasma cell leukemia
were excluded. Patients who did not receive the induc-
tion treatment were also excluded. This study was ap-
proved by the Institutional Review Board of Chonnam
National University Hwasun Hospital in accordance with
the Declaration of Helsinki.
EM was defined as death within one year of diagnosis.
Mortality rate and cause at 3, 6, and 12 months follow-
ing diagnosis was evaluated. Comorbidity score was
scored according to the Charlson Comorbidity Index
(CCI), as calculated at the time of diagnosis based on
the clinical history as well as laboratory and radiologic
tests. Age-adjusted Charlson Comorbidity Index (ACCI)
was calculated by adding the comorbidity score to the age
score, which adds 1 point per decade to ages > 40 years
[14]. Body mass index (BMI) was calculated as weight
measured in kilograms divided by the square of the
height measured in meters (kg/m2). Height and weight
at diagnosis or prior to first-line chemotherapy were
used to calculate BMI. Clinical staging was performed
using the International Staging System (ISS). The cyto-
genetic risk was classified as standard or high risk
based on conventional cytogenetic studies or fluores-
cent in situ hybridization. Patients with t(4;14),
t(14;16), or, 17p deletion were classified as high risk.
Normal cytogenetics and other cytogenetic abnormal-
ities were classified as standard risk. Treatment re-
sponse was assessed on the first day of each treatment
cycle according to the International Myeloma Working
Group criteria.
Statistical analysis
Pearson’s chi-square test for discrete variables and the
Mann-Whitney U test for continuous variables were
used to compare patient characteristics. OS was defined
as the period from the date of diagnosis to the date of
the last follow-up or death from any cause. OS was eval-
uated using Kaplan-Meier estimates and compared using
log-rank test. Univariate analysis of factors associated
with EM was performed with the χ2 test. Among the fac-
tors, those with P < 0.05 were selected and included in
the multivariate logistic regression analysis. All statistical
computations were performed using SPSS ver. 21 (SPSS,
Chicago, IL, USA). A P-value < 0.05 was considered sig-
nificant for all analyses.
Results
Patient population
The median age of the patients was 63 years (range,
38–86 years) and 43.0 % were ≥ 65 years. A total of 304
patients (56.1 %) were male. The MM type of 296 pa-
tients (54.6 %) was Immunoglobulin (Ig) G, and 20.3 %
of patients had light chain disease. With regard to the
ISS, 133 patients (24.5 %) were stage I, 191 (35.2 %)
were stage II, and 211 (38.9 %) were stage III. Of the
542 patients, 188 (34.7 %) diagnosed between 2002 and
2009, and 354 were diagnosed between 2010 and 2014.
The clinical characteristics and treatment for these two
periods are summarized in Table 1.
A total of 215 patients (39.7 %) had at least one co-
morbidity at the time of diagnosis, and 45.1 % of elderly
patients (≥ 65 years) had a concurrent comorbidity. The
median ACCI score was three for the entire group
(range, 0–9). The median BMI was 23.3 kg/m2 (range,
13.1–59.2) at the time of diagnosis. Underweight pa-
tients (< 18.5 kg/m2) accounted for 13 (2.3 %), and 16
patients (2.9 %) were obese (≥ 30 kg/m2).
All patients were treated with a regimen containing a
novel agent after the initial diagnosis. A total of 358 pa-
tients (66.1 %) received a thalidomide-based regimen as
the first-line treatment, such as cyclophosphamide,
thalidomide, and dexamethasone (CTD), or melphalan,
prednisolone, and thalidomide (MPT), or thalidomide
alone or other combinations. A total of 173 patients
(31.9 %) were treated with a bortezomib–containing
regimen such as bortezomib, melphalan, and prednisolone
(VMP), or bortezomib, cyclophosphamide, and dexa-
methasone (VCD), or bortezomib and other combinations.
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Ten patients (1.8 %) were treated with lenalidomide
and low-dose dexamethasone. One patient received the
carfilzomib, melphalan, and prednisolone regimen. Be-
cause front-line treatment with bortezomib was not
covered by health insurance in Korea at 2002–2009,
the majority of patients during this time were treated
with a thalidomide-based regimen as induction ther-
apy. In elderly patients, majority of patients (82.6 %)
were treated with a thalidomide-based regimen at
2002–2009, but 85.0 % of patients were treated with a
bortezomib-based regimen at 2010–2014 by health in-
surance. In addition, lenalidomide was not used the
front-line treatment by 2009, and eight elderly patients
(5.4 %) received the lenalidomide-based regimens as
the front-line therapy at 2010–2014.
Survival outcomes and factors associated with OS
Over a median follow up of 34.6 months, the median
OS was 56.5 months (95 % CI 48.6–64.4, Fig. 1a). The
median OS for the 2010–2014 group was longer com-
pared with the 2002–2009 group (59.2 months vs.
49.1 months, P = 0.054, Fig. 1b). This improved OS
was primarily seen in patients under 65 years of age
(not reached vs. 56.8 months, P = 0.009). There was no
significant difference in OS according to the diagnosis
period in patients over the 65 years of age (33.2 months
vs. 37.9 months, P = 0.805, Fig. 1c). Among the entire
group, a total of 233 patients (43.0 %) underwent
HDT/ASCT, and 74.1 % of patients under 65 years of
age received HDT/ASCT. The median time to HDT/
ASCT from diagnosis was 5.9 months (3.1–45.4 months).
Patients who received HDT/ASCT had significantly
longer OS compared with those who did not undergo
HDT/ASCT (76.1 months vs. 33.2 months, P < 0.001,
Fig. 1d). In young patients (< 65 years), the median OS
for patients receiving HDT/ASCT was significantly lon-
ger than those who did not undergo HDT/ASCT
(76.1 months vs. 23.5 months, P < 0.001).
We evaluated the factors associated with OS in 525 pa-
tients, excluding patients who did not have certain labora-
tory test at the initial diagnosis. Cox multivariate analysis
showed: ACCI ≥ 4 [hazard ratio (HR), 1.782; 95 % CI,
1.227–2.587; P = 0.002], BMI < 20 kg/m2 (HR 1.780, 95 %
CI 1.177–2.693, P = 0.006), ECOG performance status
(PS) ≥ 2 (HR 1.468, 95 % CI 1.064–2.025, P = 0.019), and
high risk cytogenetics (HR 1.625, 95 % CI 1.063–2.486,
P = 0.025). ISS was prognostic for OS in univariate ana-
lysis but not in multivariate analysis (Fig. 2).
Table 1 Clinical characteristics
All patients (n = 542) 2002–2009 (n = 188) 2010–2014 (n = 354) P*
Age, years (range) 63 (31–86) 63.4 (32–85) 62 (31–86) 0.678
≥ 65, n (%) 233 (43.0) 86 (45.7) 147 (41.5) 0.363
Male, n (%) 304 (56.1) 106 (56.4) 198 (55.9) 0.928
ISS, n (%)
I 133 (24.5) 52 (27.7) 81 (22.9) 0.248
II 191 (35.2) 64 (34.0) 127 (35.9) 0.705
III 211 (38.9) 70 (37.2) 141 (39.8) 0.578
Ig type, n (%)
IgG 296 (54.6) 111 (59.0) 185 (52.3) 0.173
IgA 113 (20.8) 44 (23.4) 69 (19.5) 0.319
Light chain only 110 (20.3) 31 (16.5) 79 (22.3) 0.116
ECOG PS ≥ 2, n (%) 140 (25.8) 54 (28.7) 86 (24.3) 0.304
Median BM plasma cells, % 37.5 34.7 40.0 0.236
Serum albumin, median, g/dL 3.5 3.4 3.5 0.121
Serum β2-microglobulin, median, mg/L 4300 4400 4241 0.709
Primary treatment regimen, n (%)
Thalidomide-based 358 (66.1) 161 (85.6) 197 (55.6) < 0.001
Bortezomib-based 173 (31.9) 27 (14.4) 146 (41.2) < 0.001
Lenalidomide-based 10 (1.8) 0 10 (2.8) 0.018
Carfilzomib-based 1 (0.2) 0 1 (0.3) 1.000
Performance of ASCT, n (%) 233 (43.0) 71 (37.8) 162 (45.8) 0.083
Abbreviations: N number, ISS International Staging System, Ig immunoglobulin, ECOG Eastern Cooperative Oncology Group, PS performance status, BM bone
marrow, ASCT autologous stem cell transplantation
*Comparison between the 2002–2009 and 2010–2014 cohorts
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Characteristics of EM
Of the 542 patients, 75 (13.8 %) died within 12 months
of diagnosis, 3.1 % within 3 months, and 8.6 % within
6 months. The EM rate in the 2010–2014 group was
lower (12.7 % vs. 15.9 %, P = 0.356). The causes of mor-
tality at 3, 6 and 12 months are summarized in Fig. 3.
The major cause of EM was infection and comorbidity.
The most common form of infection was septic shock
with pneumonia, and the rate of death from infection
remained constant for 12 months (35.2 % at 3 months,
36.2 % at 12 months). Pathogens and types of infection
summarized in Table 2. Mortality from comorbidity
(41.1 %) was higher than those from infection at
3 months, but it has decreased gradually to 24.0 % at
12 months. Comorbidities associated with EM were car-
diac disease (55.5 %), renal disease (22.2 %), hepatic dis-
ease (5.5 %), chronic lung disease (5.5 %), and solid
tumor (11.1 %). Death from disease progression was low
for the 3 months and then increased gradually.
Factors associated with EM
Univariate analysis showed that age > 70 years, BMI <
20 kg/m2, ECOG PS ≥ 2, ACCI ≥ 4, high lactate dehydro-
genase, low absolute lymphocyte count (≤ 1.1 × 109/L),
A B
C D
Fig. 1 a Kaplan-Meier survival curves for overall survival (OS) in all patients. b OS according to age. c OS according to the period of diagnosis.
d OS comparison between patients receiving an autologous stem cell transplantation (ASCT) versus those who did not receive ASCT0
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platelets < 100 × 109/L, serum creatinine ≥ 2 mg/dL, serum
albumin < 3.5 g/dL, and serum β2-microglobulin > 5500 mg/
L were significantly associated with EM. These vari-
ables were examined using multivariate analysis, which
identified ACCI ≥ 4, BMI < 20 kg/m2, platelets < 100 ×
109/L, and serum creatinine ≥ 2 mg/dL as factors that
independently predict EM (Table 3). The presence of
0, 1, or ≥ 2 factors was associated with a 4.1 %, 14.3 %,
or 27.4 % risk of EM (P < 0.001, Fig. 4a), respectively.
The median OS was significantly different depending
on the presence of factors associated with EM (P <
0.001, Fig. 4b).
Discussion
The introduction of novel agents with new therapeutic
mechanisms has changed the paradigm of MM therapy,
and considerably improved outcomes in patients with
this disease. Recent studies have demonstrated that im-
proved survival has been sustained following the intro-
duction of novel agents in elderly patients as well as
younger patients [13, 15]. These survival data mainly
come from studies based in Western countries, while
data for Asian patients are rare. In this study, Korean
MM patients also exhibited improved survival following
the introduction of novel agents, but improved survival
A B
C D
Fig. 2 Kaplan-Meier survival curves for overall survival (OS) according to a age-adjusted Charlson Comorbidity Index (ACCI) 4, b body mass index
(BMI) 20 kg/m2, c cytogenetic risk, and d international staging system (ISS)
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was limited to younger patients. The lack of improved sur-
vival in elderly patients may be associated with health in-
surance limitations in Korea. The use of synthetic
derivatives of thalidomide, such as lenalidomide and poma-
lidomide, were not approved in Korea during 2002–2014.
There was a 13.8 % rate of EM in patients initially
treated with novel-agent containing regimen, and the
main causes of EM were infection and comorbidity. In-
fection was reported as a major cause of morbidity and a
leading cause of death in patients with MM [16, 17].
MM patients are predisposed to infection because of im-
mune dysfunction, placement of vascular catheters, and
impaired mucosal integrity due to the effects of chemo-
therapy and radiotherapy [18, 19]. In a recent large
population-based study of over 9000 MM patients in the
period 1988–2007, the risk of infections and infection-
related death is significantly increased in MM patients
compared to controls, and the incidence of infection was
highest within the first year following diagnosis. Further-
more, the risk of infection has increased in the recent
decades [20]. In our study, the rate of death from infec-
tion was constant within a 12 month period. These re-
sults suggest that infection is still a major problem for
MM patients treated with novel-agent containing regi-
men, and the management of early infection throughout
the disease course was important to improve survival.
Another goal of this study was to identify factors asso-
ciated with EM after induction treatment. Because co-
morbidities present at diagnosis were identified as a
major cause of EM in this study, we evaluated the prog-
nostic value of ACCI. The CCI is a statistically validated
tool that assigns different weights to patients’ comorbidi-
ties to predict mortality, and can be adjusted to the pa-
tients age [14]. CCI has been demonstrated to affect
survival outcomes for various types of cancer, including
hematologic malignancies [21–23]. In patients with MM,
several reports showed that comorbidity score was asso-
ciated with diminished survival outcomes [24, 25]. Co-
morbidities such as renal impairment, impaired lung
function, and poor PS were prognostic for poor OS in
MM patients. In multivariate analysis, high ACCI (≥ 4)
was significantly associated with EM. In addition, low
BMI (< 20 kg/m2) was significantly associated with EM,
and 27.1 % of patients with low BMI died within
12 months of diagnosis. We previously reported that a
low BMI (< 20 kg/m2) at the time of diagnosis was asso-
ciated with poor survival [26]. Low BMI may reflect
involuntary weight loss caused principally by cancer-
associated cachexia [27]. High ACCI and low BMI may
Fig. 3 Etiologies of EM
Table 2 Infectious complications of early mortality
Number (%)
MDI
Pneumonia
Streptococcus pneumoniae 2 (7.4 %)
Pseudomonas aeruginosa 2 (7.4 %)
Klebsiella pneumoniae 1 (3.7 %)
Escherichia coli 1 (3.7 %)
Influenza A 1 (3.7 %)
Pneumocystis jiroveci 1 (3.7 %)
Meningoencephalitis
Streptococcus pneumoniae 1 (3.7 %)
CDI
Pneumonia 12 (44.4 %)
Unknown 6 (22.2 %)
MDI microbiologically documented infection, CDI clinical documented infection
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be associated with reduced physical function, poorer tol-
erance of treatment, and increased toxicity of chemo-
therapy. Therefore, ACCI and BMI are considered as an
important host factors to stratify the risk of myeloma
and decide treatment options.
The prognostic role of thrombocytopenia is less
understood in patients with MM. Several reports ex-
plored the prognostic role of thrombocytopenia in MM
patients with renal failure. One study showed that
thrombocytopenia (< 130 × 109/L) was related to a poor
prognosis (HR 2.150, 95 % CI 1.167–3.962, P = 0.014)
[28], whereas another study reported no association (HR
1.52, 95 % CI 0.875–2.65, P = 0.136) [29]. In the current
study, thrombocytopenia present at initial diagnosis was
a strong predictor for EM. A recent study suggested that
thrombocytopenia (< 200 × 109/L) was associated with
EM, but this was not confirmed by multivariate analysis
[13]. Further study is needed to ascertain whether
thrombocytopenia has a prognostic role, as well as to de-
termine the appropriate threshold.
This study has some limitations. Validation is an im-
portant step in developing a prognostic model. However,
the risk factors used in this study were not validated in a
separate analysis. The lack of validation step of risk fac-
tors can be a limitation of this analysis. Additionally,
number of all patients was numerous but number of pa-
tients in each group was not very large.
Conclusion
In conclusion, the rate of MM patients in novel-agent
era was 13.8 %. Major causes of EM were infection
and comorbidity. The ACCI (≥ 4), BMI (< 20 kg/m2),
thrombocytopenia, and renal failure were significantly as-
sociated with EM. Median OS times were significantly
Table 3 Univariate and multivariate analysis of risk factors associated with EM (n = 525)
Variables Univariate analysis Multivariate analysis
HR (95 % CI) P HR (95 % CI) P
Age > 70 years 2.13 (1.23–3.70) 0.007
Female 0.70 (0.42–1.17) 0.183
Body mass index < 20 kg/m2 2.72 (1.43–5.15) 0.002 2.26 (1.12–4.56) 0.022
ECOG PS ≥ 2 1.82 (1.08–3.06) 0.024
ACCI≥ 4 2.56 (1.55–4.24) < 0.001 2.23 (1.14–4.36) 0.019
LDH > 1 x ULN 1.98 (1.14–3.46) 0.015
ALC≤ 1.1 × 109/L 2.26 (1.28–4.00) 0.005
Hemoglobin < 10 g/dL 1.36 (0.81–2.27) 0.233
Platelet < 100 × 109/L 2.66 (1.59–4.42) < 0.001 2.21 (1.27–3.84) 0.005
Serum creatinine ≥ 2 mg/dL 3.52 (2.07–6.01) < 0.001 2.37 (1.18–4.76) 0.015
Serum albumin < 3.5 g/dL 1.82 (1.10–3.01) 0.020
Serum β2-microglobulin > 5500 mg/L 2.83 (1.71–4.68) < 0.001
Abbreviations: EM early mortality, ECOG Eastern Cooperative Oncology Group, PS performance status, ACCI age-adjusted Charlson comorbidity index, CCI Charlson
comorbidity index, LDH lactate dehydrogenase, ULN upper limit of normal vaule, ALC absolute lymphocyte count
A
B
Fig. 4 a EM rate and b OS according to number of risk factors
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different depending on the presence of risk factors associ-
ated with EM. The results of this study will help to iden-
tify patients at high risk for EM, and may be helpful to
more accurately predict prognosis of MM patients in the
novel-agent era.
Abbreviations
ACCI, age-adjusted Charlson comorbidity index; BMI, body mass index; CTD,
cyclophosphamide, thalidomide and dexamethasone; EM, early mortality;
HDT/ASCT, high-dose chemotherapy followed by autologous stem cell
transplantation; HR, harzard ratio; ISS, International Staging System; MM,
multiple myeloma; MPT, melphalan, prednisolone, and thalidomide; OS,
overall survival; PS, performance status; VCD, bortezomib, cyclophosphamide,
and dexamethasone; VMP, bortezomib, melphalan, and prednisolone
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